Characteristics of patients with ALL according to the allo-HCT period
| . | . | 1990-1999 . | 2000-2009 . | 2010-2019 . | P . | |||
|---|---|---|---|---|---|---|---|---|
| . | . | N = 1230 . | N = 3012 . | N = 4225 . | . | |||
| Age at allo-HCT, y | Median (IQR) | 26 | (20-37) | 37 | (25-49) | 43 | (30-55) | <.001 |
| ≤16, <25 | 552 | (44.9%) | 714 | (23.7%) | 666 | (15.8%) | <.001 | |
| ≤25, <55 | 667 | (54.2%) | 1911 | (63.4%) | 2482 | (58.7%) | ||
| 55≤ | 11 | (0.9%) | 387 | (12.8%) | 1077 | (25.5%) | ||
| WBC at diagnosis | Median (IQR) | 14 600 | (4600-51 440) | 15 810 | (5000-58 900) | 15 500 | (5125-57 545) | .23 |
| Phenotype | B | 758 | (61.6%) | 2288 | (76.0%) | 3302 | (78.2%) | <.001 |
| T | 137 | (11.1%) | 373 | (12.4%) | 527 | (12.5%) | ||
| Other | 92 | (7.5%) | 196 | (6.5%) | 193 | (4.6%) | ||
| Missing | 243 | (19.8%) | 155 | (5.1%) | 203 | (4.8%) | ||
| Karyotype | Normal | 457 | (37.2%) | 1005 | (33.4%) | 1171 | (27.7%) | <.001 |
| t(9;22) | 226 | (18.4%) | 1062 | (35.3%) | 1726 | (40.9%) | ||
| t(4;11) | 13 | (1.1%) | 64 | (2.1%) | 100 | (2.4%) | ||
| t(1;19) | 10 | (0.8%) | 64 | (2.1%) | 94 | (2.2%) | ||
| Hyperdiploid (>50) | 27 | (2.2%) | 62 | (2.1%) | 75 | (1.8%) | ||
| −7 | 5 | (0.4%) | 30 | (1.0%) | 92 | (2.2%) | ||
| Complex | 6 | (0.5%) | 54 | (1.8%) | 67 | (1.6%) | ||
| Hypodiploid (<45) | 9 | (0.7%) | 19 | (0.6%) | 33 | (0.8%) | ||
| t(8;14) | 11 | (0.9%) | 25 | (0.8%) | 22 | (0.5%) | ||
| t(14;18) | 3 | (0.2%) | 10 | (0.3%) | 14 | (0.3%) | ||
| 11q23 | 0 | (0.0%) | 8 | (0.3%) | 19 | (0.4%) | ||
| t(12;21) | 0 | (0.0%) | 2 | (0.1%) | 12 | (0.3%) | ||
| Others | 102 | (8.3%) | 383 | (12.7%) | 652 | (15.4%) | ||
| Missing | 361 | (29.3%) | 224 | (7.4%) | 148 | (3.5%) | ||
| Status at allo-HCT | CR1 | 630 | (51.2%) | 1728 | (57.4%) | 2968 | (70.2%) | <.001 |
| Subsequent CR | 233 | (18.9%) | 426 | (14.1%) | 529 | (12.5%) | ||
| Nonremission | 303 | (24.6%) | 755 | (25.1%) | 713 | (16.9%) | ||
| Missing | 64 | (5.2%) | 103 | (3.4%) | 15 | (0.4%) | ||
| Sex | Female | 503 | (40.9%) | 1388 | (46.1%) | 1868 | (44.2%) | .008 |
| Male | 727 | (59.1%) | 1624 | (53.9%) | 2355 | (55.7%) | ||
| Missing | 0 | (0.0%) | 0 | (0.0%) | 2 | (0.0%) | ||
| Donor | Related donor | 801 | (65.1%) | 1206 | (40.0%) | 1325 | (31.4%) | <.001 |
| UBM | 407 | (33.1%) | 1256 | (41.7%) | 1756 | (41.6%) | ||
| UCB | 6 | (0.5%) | 538 | (17.9%) | 1143 | (27.1%) | ||
| Missing | 16 | (1.3%) | 12 | (0.4%) | 1 | (0.0%) | ||
| Source | BM | 1139 | (92.6%) | 1822 | (60.5%) | 2064 | (48.9%) | <.001 |
| PB | 69 | (5.6%) | 640 | (21.2%) | 1017 | (24.1%) | ||
| BM + PB | 16 | (1.3%) | 12 | (0.4%) | 1 | (0.0%) | ||
| CB | 6 | (0.5%) | 538 | (17.9%) | 1143 | (27.1%) | ||
| HLA disparity | Well matched | 679 | (55.2%) | 1424 | (47.3%) | 1952 | (46.2%) | <.001 |
| Partially matched | 172 | (14.0%) | 1060 | (35.2%) | 1788 | (42.3%) | ||
| Mismatched | 91 | (7.4%) | 318 | (10.6%) | 462 | (10.9%) | ||
| Missing | 288 | (23.4%) | 210 | (7.0%) | 23 | (0.5%) | ||
| Conditioning regimen | MAC | 1176 | (95.6%) | 2512 | (83.4%) | 3004 | (71.1%) | <.001 |
| RIC | 17 | (1.4%) | 439 | (14.6%) | 1207 | (28.6%) | ||
| Missing | 37 | (3.0%) | 61 | (2.0%) | 14 | (0.3%) | ||
| ATG-based conditioning | (+) | 25 | (2.0%) | 52 | (1.7%) | 355 | (8.4%) | <.001 |
| (−) | 1153 | (93.7%) | 2894 | (96.1%) | 3854 | (91.2%) | ||
| Missing | 52 | (4.2%) | 66 | (2.2%) | 16 | (0.4%) | ||
| GVHD prophylaxis | CyA based | 1044 | (84.9%) | 1582 | (52.5%) | 1211 | (28.7%) | <.001 |
| Tac based | 109 | (8.9%) | 1301 | (43.2%) | 2926 | (69.3%) | ||
| Other | 33 | (2.7%) | 57 | (1.9%) | 74 | (1.8%) | ||
| Missing | 44 | (3.6%) | 72 | (2.4%) | 14 | (0.3%) | ||
| . | . | 1990-1999 . | 2000-2009 . | 2010-2019 . | P . | |||
|---|---|---|---|---|---|---|---|---|
| . | . | N = 1230 . | N = 3012 . | N = 4225 . | . | |||
| Age at allo-HCT, y | Median (IQR) | 26 | (20-37) | 37 | (25-49) | 43 | (30-55) | <.001 |
| ≤16, <25 | 552 | (44.9%) | 714 | (23.7%) | 666 | (15.8%) | <.001 | |
| ≤25, <55 | 667 | (54.2%) | 1911 | (63.4%) | 2482 | (58.7%) | ||
| 55≤ | 11 | (0.9%) | 387 | (12.8%) | 1077 | (25.5%) | ||
| WBC at diagnosis | Median (IQR) | 14 600 | (4600-51 440) | 15 810 | (5000-58 900) | 15 500 | (5125-57 545) | .23 |
| Phenotype | B | 758 | (61.6%) | 2288 | (76.0%) | 3302 | (78.2%) | <.001 |
| T | 137 | (11.1%) | 373 | (12.4%) | 527 | (12.5%) | ||
| Other | 92 | (7.5%) | 196 | (6.5%) | 193 | (4.6%) | ||
| Missing | 243 | (19.8%) | 155 | (5.1%) | 203 | (4.8%) | ||
| Karyotype | Normal | 457 | (37.2%) | 1005 | (33.4%) | 1171 | (27.7%) | <.001 |
| t(9;22) | 226 | (18.4%) | 1062 | (35.3%) | 1726 | (40.9%) | ||
| t(4;11) | 13 | (1.1%) | 64 | (2.1%) | 100 | (2.4%) | ||
| t(1;19) | 10 | (0.8%) | 64 | (2.1%) | 94 | (2.2%) | ||
| Hyperdiploid (>50) | 27 | (2.2%) | 62 | (2.1%) | 75 | (1.8%) | ||
| −7 | 5 | (0.4%) | 30 | (1.0%) | 92 | (2.2%) | ||
| Complex | 6 | (0.5%) | 54 | (1.8%) | 67 | (1.6%) | ||
| Hypodiploid (<45) | 9 | (0.7%) | 19 | (0.6%) | 33 | (0.8%) | ||
| t(8;14) | 11 | (0.9%) | 25 | (0.8%) | 22 | (0.5%) | ||
| t(14;18) | 3 | (0.2%) | 10 | (0.3%) | 14 | (0.3%) | ||
| 11q23 | 0 | (0.0%) | 8 | (0.3%) | 19 | (0.4%) | ||
| t(12;21) | 0 | (0.0%) | 2 | (0.1%) | 12 | (0.3%) | ||
| Others | 102 | (8.3%) | 383 | (12.7%) | 652 | (15.4%) | ||
| Missing | 361 | (29.3%) | 224 | (7.4%) | 148 | (3.5%) | ||
| Status at allo-HCT | CR1 | 630 | (51.2%) | 1728 | (57.4%) | 2968 | (70.2%) | <.001 |
| Subsequent CR | 233 | (18.9%) | 426 | (14.1%) | 529 | (12.5%) | ||
| Nonremission | 303 | (24.6%) | 755 | (25.1%) | 713 | (16.9%) | ||
| Missing | 64 | (5.2%) | 103 | (3.4%) | 15 | (0.4%) | ||
| Sex | Female | 503 | (40.9%) | 1388 | (46.1%) | 1868 | (44.2%) | .008 |
| Male | 727 | (59.1%) | 1624 | (53.9%) | 2355 | (55.7%) | ||
| Missing | 0 | (0.0%) | 0 | (0.0%) | 2 | (0.0%) | ||
| Donor | Related donor | 801 | (65.1%) | 1206 | (40.0%) | 1325 | (31.4%) | <.001 |
| UBM | 407 | (33.1%) | 1256 | (41.7%) | 1756 | (41.6%) | ||
| UCB | 6 | (0.5%) | 538 | (17.9%) | 1143 | (27.1%) | ||
| Missing | 16 | (1.3%) | 12 | (0.4%) | 1 | (0.0%) | ||
| Source | BM | 1139 | (92.6%) | 1822 | (60.5%) | 2064 | (48.9%) | <.001 |
| PB | 69 | (5.6%) | 640 | (21.2%) | 1017 | (24.1%) | ||
| BM + PB | 16 | (1.3%) | 12 | (0.4%) | 1 | (0.0%) | ||
| CB | 6 | (0.5%) | 538 | (17.9%) | 1143 | (27.1%) | ||
| HLA disparity | Well matched | 679 | (55.2%) | 1424 | (47.3%) | 1952 | (46.2%) | <.001 |
| Partially matched | 172 | (14.0%) | 1060 | (35.2%) | 1788 | (42.3%) | ||
| Mismatched | 91 | (7.4%) | 318 | (10.6%) | 462 | (10.9%) | ||
| Missing | 288 | (23.4%) | 210 | (7.0%) | 23 | (0.5%) | ||
| Conditioning regimen | MAC | 1176 | (95.6%) | 2512 | (83.4%) | 3004 | (71.1%) | <.001 |
| RIC | 17 | (1.4%) | 439 | (14.6%) | 1207 | (28.6%) | ||
| Missing | 37 | (3.0%) | 61 | (2.0%) | 14 | (0.3%) | ||
| ATG-based conditioning | (+) | 25 | (2.0%) | 52 | (1.7%) | 355 | (8.4%) | <.001 |
| (−) | 1153 | (93.7%) | 2894 | (96.1%) | 3854 | (91.2%) | ||
| Missing | 52 | (4.2%) | 66 | (2.2%) | 16 | (0.4%) | ||
| GVHD prophylaxis | CyA based | 1044 | (84.9%) | 1582 | (52.5%) | 1211 | (28.7%) | <.001 |
| Tac based | 109 | (8.9%) | 1301 | (43.2%) | 2926 | (69.3%) | ||
| Other | 33 | (2.7%) | 57 | (1.9%) | 74 | (1.8%) | ||
| Missing | 44 | (3.6%) | 72 | (2.4%) | 14 | (0.3%) | ||
ATG, antithymocyte globulin; BM, bone marrow; CyA, cyclosporin A; IQR, interquartile range; MAC, myeloablative conditioning; PB, peripheral blood; Tac, tacrolimus; UBM, unrelated bone marrow or peripheral blood; UCB, unrelated cord blood; WBC, white blood cell.